BVS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

155.70M

+1.34%

0.215

+43.33%

132.40M

+6.88%

0.125

+56.25%

158.52M

+7.35%

0.230

+9.52%

Estimates Revision

The market is revising Upward the revenue expectations for Bioventus Inc. (BVS) for FY2025, with the revenue forecasts being adjusted by 0.1% over the past three months. During the same period, the stock price has changed by 22.22%.

Revenue Estimates for FY2025

Revise Upward

+0.1%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.76%

In Past 3 Month

Stock Price

Go Up

+22.22%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast BVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BVS is USD with a low forecast of 14.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

14.00

Averages

High

15.00

Current: 0.000

Low

14.00

Averages

High

15.00

Cantor Fitzgerald

Ross Osborn

Overweight

initiated

$12

2025-07-07

Reason

Cantor Fitzgerald

Ross Osborn

Price Target

$12

2025-07-07

initiated

Overweight

Reason

Cantor Fitzgerald analyst Ross Osborn initiated coverage of Bioventus with an Overweight rating and $12 price target.

Canaccord Genuity

Caitlin Cronin

Strong Buy

Maintains

$15

2025-03-17

Reason

Canaccord Genuity

Caitlin Cronin

Price Target

$15

2025-03-17

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Bioventus Inc (BVS.O) is 9.49, compared to its 5-year average forward P/E of 22.37. For a more detailed relative valuation and DCF analysis to assess Bioventus Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

22.37

Current PE

9.49

Overvalued PE

54.14

Undervalued PE

-9.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

8.84

Current EV/EBITDA

6.62

Overvalued EV/EBITDA

10.88

Undervalued EV/EBITDA

6.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.90

Current PS

0.81

Overvalued PS

1.34

Undervalued PS

0.46

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BVS News & Events

Events Timeline

No data

News

9.5

01-01Yahoo Finance

Bravura Solutions Projects FY2026 Revenue of A$265-275 Million Amid Insider Buying

9.0

2025-12-11Globenewswire

BioVersys Initiates BV100 Phase 3 Clinical Trial, Raises CHF 76.7 Million in IPO

7.0

2025-12-05PRnewswire

Halper Sadeh Investigates Bioventus for Potential Shareholder Compensation

People Also Watch

Frequently Asked Questions

What is Bioventus Inc (BVS) stock price today?

The current price of BVS is 8.03 USD — it has increased 0.38 % in the last trading day.

What is Bioventus Inc (BVS)'s business?

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.

What is the price predicton of BVS Stock?

Wall Street analysts forecast BVS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BVS is USD with a low forecast of 14.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Bioventus Inc (BVS)'s revenue for the last quarter?

Bioventus Inc revenue for the last quarter amounts to 138.65M USD, decreased -0.23 % YoY.

What is Bioventus Inc (BVS)'s earnings per share (EPS) for the last quarter?

Bioventus Inc. EPS for the last quarter amounts to 0.05 USD, decreased -162.50 % YoY.

What changes have occurred in the market's expectations for Bioventus Inc (BVS)'s fundamentals?

How many employees does Bioventus Inc (BVS). have?

Bioventus Inc (BVS) has 930 emplpoyees as of January 11 2026.

What is Bioventus Inc (BVS) market cap?

Today BVS has the market capitalization of 664.59M USD.